FAQ

Featured FAQs

Q
Where can I go to check on the progress of your company’s development? What kind of drugs do you have under development?
A
A. Please see the Product Pipeline section under Business Outline for current progress in the development of the pipeline. You can also check for up-to-date development progress in the IR News section. Also, if you sign up for our email newsletter, we will send you the latest information available on our development progress, results announcements, and other information as soon as they become available (currently available in Japanese only).
Q
When are financial results announced?
A
A. Please refer to the IR Calendar in the IR section.

Development Information

Q
Where can I go to check on the progress of your company’s development? What kind of drugs do you have under development?
A
A. Please see the Product Pipeline section under Business Outline for current progress in the development of the pipeline. You can also check for up-to-date development progress in the IR News section. Also, if you sign up for our email newsletter, we will send you the latest information available on our development progress, results announcements, and other information as soon as they become available (currently available in Japanese only).
Q
Could you tell me about the development progress of H-1337?
A
A. H-1337 is our first in-house developed drug. We initiated Phase I/early Phase II clinical trial for the drug in the U.S. in 2018. The trial confirmed the drug’s efficacy and found no serious adverse events with regard to safety. The current schedule calls for a late-stage Phase II clinical trial to start in the U.S. in 2022, finishing in 2023. Please refer to this section for details.
Q
What kind of research are you conducting?
A
DWTI is engaged in research focused on treatments for ophthalmic diseases. We anticipate finding additional applications for the kinase inhibitors we are researching in light of their properties, and expect them to be used to treat a range of diseases outside the ophthalmology field.

Financial results, financial data

Q
When are financial results announced?
A
Please refer to the IR Calendar in the IR section.
Q
Do you have any financial results briefing materials?
A
A. Please refer to Financial Information in the IR section. The latest financial results briefing video(in Japanese only) can also be found here.
Q
When does your fiscal year end?
A
The fiscal year ends on December 31. DWTI’s business year runs from January 1 to December 31.
Q
Where can I find the latest information on financial results and other financial data?
A
A. Please refer to the IR section for information on our financial performance and results.
Q
What is DWTI’s capitalization?
A
Please refer to the Company Profile under About DWTI.
Q
What is your forecast for future performance?
A
We disclose a medium-term management plan which includes our forecasts for future performance. For details, please refer to the IR Library section (currently available in Japanese only).

About DWTI

Q
When was DWTI founded? Please tell me about the history of your company.
A
A. Our company was founded in February 1999. To learn more about our history, please see the History section under About DWTI.
Q
When was DWTI’s stock listed?
A
October 23, 2009.
Q
What does the name D. Western Therapeutics Institute signify?
A
Our company name, D. Western Therapeutics Institute, Inc. (DWTI), derives from the Drug-Western Method, the proprietary technology for which we previously held patent.
Q
Where are DWTI’s head office and R&D laboratory located?
A
Our head office is located in Nagoya, Aichi Prefecture, and our R&D laboratory is located in Tsu, Mie Prefecture.
Q
What is your Corporate Philosophy?
A
Please refer to our Corporate Philosophy.

Stock Information

Q
Where is your stock listed?
A
DWTI’s stock is listed on the Tokyo Stock Exchange GROWTH market.
Q
What is DWTI’s securities code?
A
4576.
Q
What is your stock’s trading unit?
A
DWTI stock trades in units of 100 shares.
Q
When is DWTI’s general shareholders’ meeting?
A
The general meeting of shareholders is held in March.
Q
Does DWTI have a shareholder benefit program?
A
We do not currently have a shareholder benefit program.
Q
Please tell me about dividends.
A
DWTI has not paid out dividends to date. At present, our priority is on maintaining internal reserves while safeguarding our capacity for ongoing research and development activities. However, we believe providing returns to shareholders is an important management issue, and will consider paying out dividends while taking into account current performance and financial conditions.
Q
Which financial institution acts as the agent managing DWTI’s shareholder registry?
A
Sumitomo Mitsui Trust Bank, Ltd.
Q
Who should I contact with questions about DWTI’s stock-related administrative procedures?
A
For inquiries regarding procedures such as a change of address or name, or to request the paperwork for such procedures, please contact your local securities broker.
For general inquiries regarding DWTI’s stock, the Stock Transfer Agency Business Planning Department of Sumitomo Mitsui Trust Bank, the agent managing DWTI’s shareholder registry, also accepts inquiries. The toll-free number in Japan is 0120-782-031.
Q
How many shares has DWTI issued?
A
Please refer to the IR section for stock information.